Covalon Technologies Ltd.

Equities

COV

CA22282D3022

Biotechnology & Medical Research

Market Closed - Toronto S.E. 02:34:49 2024-04-24 pm EDT 5-day change 1st Jan Change
0.97 CAD -11.82% Intraday chart for Covalon Technologies Ltd. -19.17% -8.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call
Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows; Up 17.8% MT
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows MT
Covalon Technologies Narrows Fiscal Q4 Loss, Revenue Grows MT
Covalon Technologies Ltd. Announces Interim Chief Financial Officer Changes CI
Covalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - Operations CI
Covalon Technologies Brief: Reporting 2023-Q4 revenue of $6.9 million, an increase of 28%, and net loss from continuing operations of $2.9 million, an improvement of $1.2 million MT
Covalon Technologies Ltd. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Covalon Technologies Ltd. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Covalon Technologies Ltd. Announces Chief Executive Officer Changes CI
Covalon Technologies Ltd. Announces Executive Changes CI
Covalon Technologies Appoints MedTech Executive Brent Ashton as its New Chief Executive MT
Covalon Technologies Brief: Appointing "Experienced" MedTech Executive Brent Ashton as New CEO MT
Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in Chicago CI
Transcript : Covalon Technologies Ltd. - Special Call
Covalon Technologies Names Interim CEO; Begins Search for Permanent CEO MT
Covalon Technologies Ltd. Announces Chief Executive Officer Changes CI
Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent Director CI
Transcript : Covalon Technologies Ltd., Q3 2023 Earnings Call, Aug 16, 2023
Covalon Technologies Reports Total Q3 Revenue Increased 39% to $6.3 Million; MT
Covalon Technologies Brief: Both net loss and net loss from continuing operations for the three months ended June 30, 2023 was $0.5 million or $0.02 per share MT
Covalon Technologies Brief: Total revenue for the three months ended June 30, 2023 increased 39% to $6.3 million MT
Tranche Update on Covalon Technologies Ltd.'s Equity Buyback Plan announced on May 25, 2022. CI
Covalon Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Chart Covalon Technologies Ltd.
More charts
Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.
More about the company
  1. Stock Market
  2. Equities
  3. COV Stock
  4. News Covalon Technologies Ltd.
  5. Covalon Technologies : Gains Near 3% as Swings to Fiscal Q2 Net Income Year Over Year